Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
November 29, 2014, 12:37:05 AM

Login with username, password and session length


Members
  • Total Members: 24078
  • Latest: Rlhayn
Stats
  • Total Posts: 647776
  • Total Topics: 49368
  • Online Today: 167
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 4
Guests: 133
Total: 137

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: CROI2010: Predictors of Attaining <1 copies/mL- Cross-sectional Study  (Read 1321 times)

0 Members and 1 Guest are viewing this topic.

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
Interesting to know that 60% had confirmed (2 consecutive) HIV-RNA values of <1 copies/mL.


Predictors of Attaining <1 Plasma HIV/RNA copies/mL in a Large Italian Cross-sectional Study

Background:  Predictors of attaining <1 HIV-RNA copies/mL in plasma by antiretroviral therapy (ARV) have not been identified in large studies, but may be very important in the long-term management of HIV-infected patients.

Methods:  Cross-sectional study of patients (pts) on ARV followed at our center, with both HIV-RNA <50 copies/mL at the last 2 viral loads (VL) tested by Versant bDNA before testing by Versant kPCR and HIV-RNA <50 copies/mL at the 2 subsequent VLs tested by Versant kPCR (limit of quantification 1 copies/mL), were included in this analysis. Logistic regression was used at multivariable analysis. Main outcome measure: HIV-RNA <1 copies/mL. The detectability ratio (DR) was calculated as the number of HIV-RNA values of >50 copies/mL divided by the number of HIV-RNA values measured since the start of ARV up to the first kPCR testing. “New-drugs”-based regimens were those containing enfuvirtide, darunavir/r, raltegravir, maraviroc, or etravirine.

Results:  Since March 2009, all patients at our center had VL tested by Versant kPCR. Seven hundred thirty-nine patients (77% males) fulfilled inclusion criteria; at first kPCR testing, patients had a median (Q1, Q3) age of 46.6 (range: 42.2 to 51.5) years, were on ARV since a 11.1 (5.3 to 13.9) years, on their last ARV regimen since 1.4 (0.6 to 2.9) years, had 545 (390 to 736) CD4/mcL, a CD4 nadir of 213 (107 to 297) cells/mcL, and a DR of 0.42 (0.2 to 0.65); 135 (18.3%) were in C3 CDC stage, 275 (37.21%) were on-therapy with a PI/r-based regimen, 139 (18.81%) with an unboosted-PI-based, 204 (27.6%) with a NNRTI-based, 46 (6.22%) with a NRTI-based, and 75 (10.15%) with a “new-drugs”-based regimen. Four hundred forty-six of 739 (60.3%) had confirmed (2 consecutive) HIV-RNA values of <1 copies/mL. Variables independently associated with <1 HIV-RNA copies/mL were: female vs male gender (OR = 2.017; 95%CI 1.296 to 3.184; P =0.002), the DR (0.804 per 0.2-unit increment; 0.703 to 0.919; P =0.002), and being on a NNRTI- vs a PI/r-based regimen (1.871; 1.273 to 2.845; P =0.007). Age, risk factor, duration of ARV and duration of the last ARV, nadir CD4 count, CDC stage, CD4 count at first kPCR testing, and being on-therapy with a NRTI-, an unboosted PI- or a “new-drugs”-based regimen (compared to a PI/r-based regimen), were not independently associated with the ability of attaining <1 HIV-RNA copies/mL.

Conclusions:  Treatment with NNRTI- vs a PI/r-based regimen, female gender and the DR independently predict the ability of attaining <1 HIV-RNA copies/mL.[/navy]


Source
« Last Edit: February 23, 2010, 05:13:58 PM by John2038 »

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.